LONDON BROKER RATINGS: Bernstein reinitiates Convatec at 'outperform'
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
| Price | 67.35p on 06-02-2026 at 19:40:06 |
|---|---|
| Change | 0.05p 0.07% |
| Buy | 67.85p |
| Sell | 67.30p |
| Last Trade: | Buy 1,525,000.00 at 67.10885p |
| Day's Volume: | 2,351,289 |
| Last Close: | 67.35p |
| Open: | 64.80p |
| ISIN: | GB00BL6NGV24 |
| Day's Range | 64.80p - 67.55p |
| 52wk Range: | 43.94p - 100.80p |
| Market Capitalisation: | £650.99m |
| VWAP: | 67.08638p |
| Shares in Issue: | 966.58m |
Dr. Martens (DOCS) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 1,525,000 | 67.10885p | Suspected BUY Trade |
16:35:39 - 06-Feb-26 |
| Buy* | 110,000 | 67.23p | Ordinary |
16:35:39 - 06-Feb-26 |
| Buy* | 1,317 | 67.35p | Automatic Execution |
16:35:09 - 06-Feb-26 |
| Buy* | 199,090 | 67.35p | Suspected BUY Trade |
16:35:09 - 06-Feb-26 |
| Sell* | 193 | 67.30p | SI Trade |
16:29:51 - 06-Feb-26 |
| Buy* | 1,023 | 67.564p | Ordinary |
16:28:32 - 06-Feb-26 |
| Buy* | 459 | 67.45p | Automatic Execution |
16:28:10 - 06-Feb-26 |
| Buy* | 7 | 67.40p | Automatic Execution |
16:28:10 - 06-Feb-26 |
| Sell* | 1 | 67.35p | Automatic Execution |
16:27:43 - 06-Feb-26 |
| Sell* | 1,090 | 67.35p | Automatic Execution |
16:27:43 - 06-Feb-26 |
Dr. Martens (DOCS) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 30th Jan 2026 11:15 am | RNS | Total Voting Rights |
| 29th Jan 2026 7:00 am | RNS | EBT Share Purchase |
| 27th Jan 2026 7:00 am | RNS | Holding(s) in Company |
| 27th Jan 2026 7:00 am | RNS | Q3 FY26 Trading Statement |
| 15th Jan 2026 9:24 am | RNS | Director/PDMR Shareholding |
| 31st Dec 2025 11:11 am | RNS | Total Voting Rights |
| 31st Dec 2025 11:11 am | RNS | Total Voting Rights |
| 12th Dec 2025 3:00 pm | RNS | Director/PDMR Shareholding |
| 12th Dec 2025 7:00 am | RNS | Director/PDMR Shareholding |
| 8th Dec 2025 7:00 am | RNS | Director/PDMR Shareholding |